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1,25-(OH)2D receptors are decreased in parathyroid glands from
chronically uremic dogs. 1 ,25-(OH)2D has been shown to suppress the
synthesis and secretion of parathyroid hormone in vivo and in dispersed
parathyroid cell cultures. Control of transcription by 1 ,25-(OH)2D is
believed to be mediated by interaction of this hormone with a specific
receptor within target cells. We have examined the 1 ,25-(OH)2D
receptor in parathyroid glands from normal dogs and chronic renal
failure dogs. The levels of receptor were fourfold lower in parathyroid
extracts from these uremic dogs than in those from normal dogs (109
11 vs. 446 61 fmol/mg protein). No differences were observed in the
binding affinity for l,25-(OH)2D or in the sedimentation in sucrose
density gradients. Since this receptor has been shown to be upregulated
by 1 ,25-(OH)2D, our findings of lower levels of receptor could be
attribed to decreased serum concentrations of 1,25-(OH)2D in chroni-
cally uremic animals. Regression analysis of log serum I ,25-(OH)2D
versus log receptor content yielded a correlation coefficient of 0.62 with
P < 0.02. Decreased receptor content showed a negative correlation
with serum N-terminal PTH (r = 0.71 and P < 0.01). It is likely that this
reduced 1,25-(OH)2D receptor number in the parathyroid glands of
chronically uremic animals renders the glands less responsive to the
inhibitory action of 1 ,25-(OH)2D on the synthesis and secretion of PTH,
and may contribute to the hyperparathyroidism associated with chronic
renal failure.
It is well established that nearly all patients with chronic renal
failure develop secondary hyperparathyroidism. Although hy-
pocalcemia is thought to be the major factor responsible for the
development of secondary hyperparathyroidism [I], recent
studies indicate that 1 ,25-dihydroxyvitamin D [1 ,25-(OH)2D]
may act directly on the parathyroid glands to alter the secretion
[2, 3] and synthesis [4, 5] of parathyroid hormone (PTH).
Suppression of PTH synthesis is at the transcriptional level [6].
Since this suppression occurs at physiological concentrations,
the lower levels of 1 ,25-(OH)2D associated with chronic renal
failure presumably would allow a higher rate of synthesis of
PTH. Control of gene transcription by 1 ,25-(OH)2D is thought
to be mediated by a receptor protein in target cells that has high
affinity and high specificity for this vitamin D metabolite [7].
Several studies have shown that the biological response to
1 ,25-(OH)2D is determined by the content of this receptor in the
target cell [8, 9].
Korkor showed that the parathyroid glands from chronic
renal failure patients contained nearly three times less receptor
than that found in parathyroid adenomas [10]. No values were
available for the receptor content in normal human parathyroid
glands. Recently, Merke and co-workers found that in acutely
uremic rats, six days after a sub-total nephrectomy, the para-
thyroid glands contained only half the amount of receptor found
in the parathyroid glands of sham-operated controls [11]. In this
paper, we present data comparing, for the first time, the
1 ,25-(OH)2D receptor in the parathyroid glands of acutely and
chronically uremic dogs to that in normal dogs.
Methods
Animals
Adult mongrel female dogs, 15 to 25 kg, were used in this
study. Uremic dogs were produced by 2/3 infarction of the left
kidney followed seven days later by removal of the right
kidney. Both nephrectomized and normal dogs received 400 g/
day of a standard dog chow diet containing 1.6% calcium and
0.9% phosphorus. Uremic dogs were maintained for 2 to 18
months; normal dogs were maintained for four weeks.
Receptor preparation
Parathyroid glands along with the attached thyroid glands
were removed from uremic and untreated normal dogs, imme-
diately placed in ice-cold phosphate-buffered saline, and trans-
ported to the lab. Parathyroid glands were dissected from the
thyroid glands while keeping the tissue cold. The parathyroid
glands were weighed and then homogenized in ice-cold TEDK-
300 buffer (10 m Tris-HCI, pH 7.4, 1.5 mM EDTA, 5 mM
dithiothreitol, and 300 mM KCI). All procedures were carried
out as rapidly as possible (within 30 minutes) and at 0 to
minimize degradation of the receptor. The homogenates were
centrifuged at 100,000 x g for 60 minutes. The supernatant was
aliquotted, frozen immediately in liquid nitrogen, and stored at
—80° until assayed for receptor. Samples were assayed within
one week of preparation although no loss of binding activity
was noted in samples stored for as long as six months at —80°.
Binding assay
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Aliquots of the cytosol (50 d) were mixed with 1 ,25-(OH)2D-
[26,27 methyl-3H]D3 (176 Cilmmol) at concentrations ranging
from 0.1 to 2.0 nM. Nonspecific binding was measured in the
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presence of a 250-fold excess of unlabeled 1 ,25-(OH)2D. The
samples were incubated at 00 for four hours, and the bound and
free l,25-(OH)2D were separated by hydroxylapatite adsorption
[121. Receptor content of the sample (Nmax) and affinity for
1 ,25-(OH)2D (Kd) were determined as outlined by Scatchard
[13].
Sucrose density gradient analysis
Cytosol samples (200 jsl) were incubated with 1 nM 1,25-
(OH)2D-[26,27 methyl-3H]D1 with and without 100 flM unla-
beled 1 ,25-(OH)2D for two hours at 0°. The samples were
treated with charcoal/dextran to remove excess I ,25-(OH)2D
and then layered onto pre-chilled (0°) 5 to 20% sucrose gradi-
ents. Gradients were centrifuged for 40 hours at 40,000 rpm in
a SW-40 rotor (Beckman Instruments Co., Fullerton, Califor-
nia, USA). Fractions of 15 drops were collected from the
bottom, mixed with 5 ml Ready-Solve (Beckman Instruments)
and tritium was measured in a Beckman LS-2800 scintillation
counter. The sedimentation coefficient was calculated using
ovalbumin (3,7 S) and albumin (6.0 S) as standards.
Other analyses
Phosphorus and creatinine were determined with a Multistat
111+ (Instrumentation Laboratories, Lexington, Massachu-
setts, USA). Total serum calcium was measured by atomic
absorption spectrophotometry (Perkin-Elmer, Model 503, Nor-
walk, Connecticut, USA). Ionized serum calcium was deter-
mined using the Ionized Calcium Analyzer Model SS-20 from
Orion Biomedical (Boston, Massachusetts, USA). Serum N-
terminal PTH was measured by radioimmunoassay as previ-
ously described [14]. Serum 1 ,25-(OH)2D was determined by
the receptor binding assay of Reinhardt et a! [151. Protein was
measured by the method of Bradford [16] using the Bio-Rad
Protein Reagent (Bio-Rad, Richmond, California, USA) using
ovalbumin (Sigma Chemical Co., St. Louis, Missouri, USA) as
standard. All data are expressed as mean SEM.
Results
Analysis of serum from the normal and chronic renal failure
(CRF) dogs showed no differences in total or ionized calcium.
As expected, serum phosphorus was higher in the CRF dog
(10.7 2.7 vs. 4.4 0.5 mg!dl). The degree of renal insuffi-
ciency was assessed by the serum creatinine. The creatinine
values were 5.46 1.6 mgldl in the CRF dogs compared to 0.65
0.05 mgldl in the normal dogs. The CRF dogs had developed
hyperparathyroidism as indicated by the higher values of serum
N-terminal PTH (2.03 0.84 vs. 0.10 0.02 ng/ml). Serum
1 ,25-(OH)2D levels were significantly lower in the CRF dogs
(11.1 1.6 vs. 29.6 3.9 pg/mI; Fig. 1).
The 1,25-(OH)2D receptor in the dog parathyroid extracts
was characterized by sucrose density gradient analysis since
the receptor from this source had not been studied previously.
Figure 2 shows sedimentation profiles for receptor preparations
isolated from parathyroid glands from a normal and a CRF dog
that were prelabeled with 1 flM tritiated I ,25-(OH)2D. Inclusion
of 100 n unlabeled l,25-(OH)2D during the labeling totally
abolished the receptor peak in the gradients (not shown). The
1 ,25-(OH)2D receptor from both sources sedimented at 3.4 5,
the value reported for receptor from a number of species and
tissues, indicating that the 1 ,25-(OH)2D binding in these prep-
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Fig. 2. Sucrose density gradient profiles for 1 ,25-(OH),D receptor
from normal (•) and uremic (0) dog parathyroid glands. Cytosols
prepared from the parathyroid glands from a normal and a uremic dog
were incubated with 1 nt'i 1 ,25-(OH)2-13H]D3 for 2 hours at 0, treated
with charcoal/dextran, and sedimented through 5 to 20% sucrose
gradients. Inclusion of 100 nM unlabeled, 1,25-(OH)2D3 during the
incubation totally abolished the tritium peaks (not shown). Sedimenta-
tion standards were bovine serum albumin (6.0 S) and ovalbumin (3.7
S).
arations are to the intact 1 ,25-(OH).,D receptor. This analysis
also shows the absence of contaminating serum vitamin D
binding protein which, if present, would sediment at 6.0 S and
appear as a shoulder on the 1 ,25-(OH).,D receptor peak.
The content of receptor in the extracts and the affinity for
1 ,25-(OH)2D were determined by incubating the samples with
tritiated ligand for four hours at 0° in the absence and presence
of a 250-fold excess of unlabeled 1 ,25-(OH)2D to get total and
non-specific binding, respectively. Scatchard plots of receptor
binding for one normal and one CRF dog are shown in Figure 3.
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Fig. 1. Serum creatinine, PTH, and I,25-(OH)2D in normal and uremic
dogs. Shaded bars represent values for normal dogs (N = 11); open bars
represent values for uremic dogs (N = 4). The data are expressed as
mean standard error.
6.OS 3.7S
1000
800
600
Brown et al: Vitamin D receptors in uremia 21
B, fmol/mg protein
Fig. 3. Scatchard analysis of specific binding of I ,25-(OH)2D3 by
cytosols prepared from normal and uremic dogs. Cytosols were incu-
bated with 1 ,25-(OH)2-[3H]D3 (0.1 to 2.0 nM) for 4 hours at 0, and bound
ligand was quantitated using the hydroxylapatite method [12]. Non-
specific binding was assessed in the presence of a 250-fold molar excess
of unlabeled 1 ,25-(OH)2D3. Specific binding was analyzed as outlined
by Scatchard [131.
The slopes of the lines, which are inversely proportional to the
Kd for 1 ,25-(OH)2D binding, are roughly the same indicating no
alteration in receptor affinity in chronic uremia. The x-inter-
cepts give the receptor content of the sample. The receptor
content, or Nmax, is clearly much less in the parathyroid extract
from the CRF dog than that from the normal dog. The Nmax
values are expressed as fmol receptor/mg protein.
The binding data for the normal and CRF dogs are shown in
Figure 4. The Nmax in the CRF dogs was 109 11 (mean sEM)
fmol receptor/mg protein compared to 446 61 in the normal
dogs. The Kd values were not significantly different.
We examined the correlation between Nmax and the serum
levels of 1,25-(OH)2D and PTH. 1,25-(OH)2D has been demon-
strated to up-regulate its receptor both in vivo and in cell
culture [17—20]. Figure 5 shows the positive correlation between
log serum l,25-(OH)2D and log Nmax. Regression analysis
yielded a correlation coefficient of 0.62 with P < 0.02. A good
correlation was also noted between serum N-terminal PTH and
Nmax. When the dataare plotted as log PTH versus log Nmax,
we obtained a correlation coefficient of 0.71 with P < 0.01.
Thus, the decrease in receptor content is accompanied by an
increase in serum PTH.
Discussion
The direct action of l,25-(OH)2D on the parathyroid glands
provides an important negative feedback for PTH secretion.
LOG
Fig. 5. Correlation between serum I,25-(OH)2D and receptor content
(N,,) of the parathyroid glands. The values for log serum I ,25-(OH)2D
and log Nmax for all dogs in the study (normal and uremic) are plotted.
Correlation coefficient and P values were determined by linear regres-
sion analysis.
This vitamin D metabolite has been shown to alter the ultra-
structure of the gland [2], to decrease serum PTH [3], and to
suppress transcription of the PTH gene [6]. The sensitivity of
parathyroid cells in culture to suppression of PTH secretion by
calcium is increased by 1,25-(OH)2D [21]. This finding has been
confirmed in vivo [22].
Many of the biological actions of 1 ,25-(OH)2D are thought to
be mediated by interaction with a high affinity receptor present
in target cells. Specific binding of 1 ,25-(OH)2D to parathyroid
cells was first noted by Henry and Norman [23]. Brumbaugh,
Hughes and Haussler demonstrated the existence of a receptor
protein in parathyroid glands with high affinity and specificity
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Fig. 4. Summary of I ,25-(OH)2D receptor content (N,,,) and binding
affinity (Kd) in cytosols from normal and uremic dogs. Nmax and Kd
values are presented for 11 normal dogs (shaded bars) and 4 uremic
dogs (open bars). Data are present as mean standard error. P values
were calculated by the Student t-test.
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Fig. 6. Correlation between serum PTH and 1,25-(OH)2D receptor
content (Nm) of the parathyroid glands. The values for log serum PTH
and log Nmx for all dogs in the study (normal and uremic) are plotted.
Correlation coefficient and P values were determined by linear regres-
sion analysis.
for 1 ,25-(OH)2D, and sedimentation properties similar to that
for l,25-(OH)2D receptor isolated from other tissues 1241.
Although the mechanism by which the receptor carries out the
nuclear actions of l,25-(OH)2D is not fully understood, it is
clear that the receptor content determines the response of the
target cell to l,25-(OH)2D [8, 91.
In the present study, we have shown that the receptor
content in the parathyroid glands of chronically uremic dogs is
reduced, compared to normal dogs, with no alteration in
binding affinity or sedimentation properties. The receptor con-
tent is expressed as fmol receptor per mg protein. Data from our
group (Dr. J. Morrissey, unpublished data) indicates that the
DNA content of the enlarged parathyroid glands of dogs made
uremic by our procedure is nearly identical to that in normal
dogs. This finding agrees with that of Merke et al [lii for the
uremic rat. Therefore, since hyperplasia is the mechanism for
gland enlargement in the chronically uremic dog, our data also
represent a decreased receptor content per cell.
These findings extend those of Korkor [10] showing less
receptor in parathyroid glands of chronic renal failure patients
than in parathyroid adenomas or in the glands of kidney
transplant patients. No values were available for normal humn
parathyroid glands, but it was assumed that the values for the
glands from transplant patients or for the adenomas were closer
to the normal level of 1 ,25-(OH)2D receptor. Our results con-
firm this assumption.
The cause of this decrease in the hyperplastic gland is
unclear. A major concern is that the low receptor values in the
CRF dogs may be the result of increased ex vivo degradation
since it appears that proteolysis is activated in uremic tissues.
We have not compared ex vivo degradation directly in our
preparations because of limited amounts of tissue. However,
tissue from both normal and uremic dogs was placed immedi-
ately upon removal in ice-cold saline, transported to the lab and
homogenized on ice within 30 minutes to minimize proteolysis.
Furthermore, preliminary results show that the 1 ,25-(OH)2D
receptor isolated in an identical fashion from the parathyroid
glands of acutely uremic dogs (4 to 15 days post-nephrectomy
and serum creatinine 12.8 2.7 mg/dl) was slightly but not
significantly less than normal (340 60, mean SEM), suggest-
ing that uremia per se does not cause an increased receptor
degradation. Thus, at this point we believe that the decreased
receptor content in chronic renal failure dog parathyroid glands
is physiologically important.
The factors responsible for the decreased receptor content in
the parathyroid glands are not known. The best candidate is
I ,25-(OH)2D which has been shown to increase its receptor in
vivo and in cell culture [17—201. The serum levels of 1,25-
(OH)2D in the CRF dogs in our study are reduced by threefold.
A similar decrease in l,25-(OH)2D was seen in Korkor's
chronic renal failure patients compared to the transplanted
patients and patients with parathyroid adenomas [10]. Merke
and co-workers also found that after six days the I ,25-(OH)2D
levels in their acutely uremic rats had dropped by 50% [11]. In
the present study, regression analysis revealed a positive cor-
relation between serum 1 ,25-(OH)2D and Nmax, although a
correlation within each experimental group was not observed.
Whether the levels of serum 1 ,25-(OH)2D determine the content
of 1 ,25-(OH)2D receptor in the parathyroid gland is not yet
clear.
We also found a negative correlation between serum PTH
and Nmax, but again there was no correlation within the
experimental groups. Presently, there is no evidence that PTH
regulates the 1 ,25-(OH)2D receptor in any tissue or cell culture
system. It is likely then that this correlation results from the
well established role of 1 ,25-(OH)2D in suppressing the synthe-
sis and secretion of PTH. Recently, Delmez, Tindira and
Grooms [25] have shown in patients on maintenance hemodial-
ysis that the administration of intravenous 1 ,25-(OH)2D has a
direct inhibitory effect on PTH release, confirming our initial
observations [3]. Moreover, part of this effect may be mediated
by lowering the "set point" making the parathyroid glands
more sensitive to calcium. Although it has not been rigorously
proven that the 1 ,25-(OH)2D receptor plays a role in suppress-
ing PTH synthesis and determining the set point for calcium,
the time course for these changes supports receptor involve-
ment. Therefore, the fourfold drop in receptor content of the
parathyroid glands observed in our chronic renal failure dogs,
combined with the threefold decrease in the serum levels of
l,25-(OH)2D would greatly diminish the normal feedback con-
trol by 1 ,25-(OH)2D and contribute to the hyperparathyroidism
associated with chronic renal failure.
Reprint requests to Alex J. Brown, Washington University School of
Medicine, Department of Medicine, Renal Division, 4949 Barnes Hos-
pital Plaza, Box 8126, St. Louis, Missouri 63110, USA.
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